FDA Adverse Event System Could Be Perfected At "Modest" Cost - Woodcock

FDA needs a "modest" funding increase to perfect its adverse drug event reporting and surveillance systems, Center for Drug Evaluation & Research Director Janet Woodcock, MD, maintained during a Feb. 1 Senate Health Committee hearing on adverse drug events.